Top Biotech Companies in Seattle, WA (59)
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.
Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.
Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.
PreemptiveAI is building the foundation model that maps human physiology/pathology and predicts health outcomes in real-time via biomedical signals from smartphones and wearable devices.
Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale. In doing...
LifeNet Health helps save lives, restore health and give hope to thousands of patients each year. LifeNet Health is the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.
Outpace Bio is a venture-backed biotechnology company building a platform to create next-generation smart cell therapies. Our world-class scientific team is developing cell therapies that intervene in complex biology in ways that small molecules and biologics cannot. Our rich platform combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. We...
Founded in 1996, PSC Biotech Corporation was created with the vision of providing life science companies unmatched support. To date, PSC Biotech Corporation now serves 1000 clients in more than 35 countries worldwide through professional services consulting, cloud-based software solutions, pharmaceuticals contract manufacturing, life science investment consulting, and metrology services. PSC Biotech Corporation has six unique divisions within the parent company...
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our...
Gilead Sciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader in HIV and maintains a top position in CAR‑T (Yescarta) while building a credible oncology footprint. Leadership is reinforced by durable HIV demand across treatment and prevention, with new lenacapavir offerings extending the franchise.
Resilient & Sustainable Growth: Recent results show modest headline growth with stronger momentum in the core base business and management guiding to continued base‑business expansion in 2026. COVID normalization and CAR‑T competition moderate the pace, but HIV and liver disease strength provide steady underpinning.
Future-Ready Strategy: The pipeline advances lenacapavir‑based regimens and multiple oncology programs, with near‑term launches and read‑throughs that can support growth beyond 2026. Prevention initiatives and oncology scaling are positioned as key execution pillars for medium‑term expansion.
We believe in harnessing science for human good. And so we work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing to helping launch new drugs, to offering new perspectives through data - all drawing from a deep...
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+...
Bridge the data gap. Augment your experimental data with AI-generated datasets and harmonized public data to get insights in minutes instead of months.
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr....
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials...
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover...
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide...
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
Enabling the next generation of breakthroughs in treating human disease.
